Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides.
Asthma is an inflammatory disease of the airways that is induced by Th2 cytokines and inhibited by Th1 cytokines. Despite a steady increase in the incidence, morbidity, and mortality from asthma, no current treatment can reduce or prevent asthma for a prolonged period. We examined the ability of unmethylated CpG oligodeoxynucleotides (ODN), which are potent inducers of Th1 cytokines, to prevent the inflammatory and physiological manifestations of asthma in mice sensitized to ragweed allergen. Administration of CpG ODN 48 h before allergen challenge increased the ratio of IFN-gamma to IL-4 secreting cells, diminished allergen-induced eosinophil recruitment, and decreased the number of ragweed allergen-specific IgE-producing cells. These effects of CpG ODN were sustained for at least 6 wk after its administration. Furthermore, there was a vigorous Th1 memory response to the recall Ag, inhibition of peribronchial and perivascular lung inflammation, and inhibition of bronchial hyperresponsiveness 6 wk after administration of CpG ODN. Administration of CpG ODN in IFN-gamma -/- mice failed to inhibit eosinophil recruitment, indicating a critical role of IFN-gamma in mediating these effects. This is the first report of a treatment that inhibits allergic lung inflammation in presensitized animals for a prolonged period and thus has relevance to the development of an effective long term treatment for asthma.
Sur
S
S
Division of Allergy and Immunology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555, USA. Sasur@utmb.edu
Wild
J S
JS
Choudhury
B K
BK
Sur
N
N
Alam
R
R
Klinman
D M
DM
D000485:Allergens / Q000276:immunology; D000818:Animals; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D003562:Cytidine / Q000627:therapeutic use; D015226:Dinucleoside Phosphates / Q000627:therapeutic use; D004195:Disease Models, Animal; D005260:Female; D006151:Guanosine / Q000627:therapeutic use; D007073:Immunoglobulin E / Q000096:biosynthesis; D007371:Interferon-gamma / Q000378:metabolism; D015847:Interleukin-4 / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008817:Mice, Mutant Strains; D009330:Nebulizers and Vaporizers; D009838:Oligodeoxyribonucleotides / Q000627:therapeutic use*; D010940:Plant Proteins / Q000276:immunology; D011058:Pollen / Q000276:immunology; D011657:Pulmonary Eosinophilia / Q000517:prevention & control; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D013997:Time Factors; D014132:Trachea / Q000187:drug effects
D000485:Allergens; D018926:Anti-Allergic Agents; D003562:Cytidine; D015226:Dinucleoside Phosphates; D006151:Guanosine; D007073:Immunoglobulin E; D007371:Interferon-gamma; D015847:Interleukin-4; D009838:Oligodeoxyribonucleotides; D010940:Plant Proteins; C015772:CpG dinucleotide